Pfizer

Cell and Molecular Biologist (Non PhD)

Posted on: 7 Mar 2021

Cambridge, MA

Job Description

Why Patients Need You

Pfizers purpose is to deliver breakthroughs that change patients lives. Research and Development is at the heart of fulfilling Pfizers purpose as we work to translate advanced science and technologies into the therapies and vaccines that matter most. Whether you are in the discovery sciences, ensuring drug safety and efficacy or supporting clinical trials, you will apply cutting edge design and process development capabilities to accelerate and bring the best in class medicines to patients around the world.

What You Will Achieve

As a Scientist, you will be at the center of our operations and youll find that everything we do, every day, is in line with an unwavering commitment to quality. You will be part of a team that is addressing the critical task of rejuvenating our pipeline with innovative, differentiated First-In-Class/ Only-In-Class programs in the years to come.

Pfizers Rare Disease Research Unit (RDRU) is focused on developing therapies for rare inherited diseases, including rare muscle, cardiac, and neurological disorders. The successful candidate will be a member of the rare cardiac disease research team and will be responsible for establishing preclinical biochemical- and cell-based assays to enable the efficacy of lead compounds to be established.

In vivo (rodent) experience is desired, to assist in the establishment of rare cardiac disease models.

The candidate is expected to have excellent problem solving, critical thinking, and presentation skills (written and oral) and will need to effectively communicate with internal and external partners.

It is your innovative scientific temperament that will help in making Pfizer ready to achieve new milestones and help patients across the globe.

How You Will Achieve It

* Contribute to achievement of goals of the team and influence at the work group/project team level.
* Design and conduct experiments that advance the development of candidate therapies for rare cardiac diseases.
* Perform experimental studies, carry out data analyses and interpretation, record results in an electronic lab notebook, and stay abreast of novel relevant findings from the literature.
* Prepare and present experimental results to project teams.
* Interface with internal interdisciplinary teams.
* Support in vitro work for other projects in the RDRU portfolio as needed.
* Comply with all safety training and good laboratory practices.

Qualifications

Must-Have

* B.S. with 6+ years of experience in biochemistry, cell biology, or a related discipline.
* Familiarity with standard cell and molecular biology methods including but not limited to cell culture, siRNA and plasmid transfections, immunoassays such as ELISAs and western blotting, and quantitative real-time PCR.
* Hands-on experience working with in vitro and in vivo models of heart disease preferred.
* Experience with culturing induced pluripotent stem cells and cardiomyocytes is desirable.
* Must be willing to work with live rodents and cells/tissues of human origin.
* Ability to use appropriate software to perform analysis of data.
* Excellent organization and planning skills, the ability to work in a fast-paced environment independently or as part of a team, strong motivation with a dedicated work ethic.
* Excellent verbal and written communication skills.
* Creativity, self-motivation and the ability to work independently including analysis and troubleshooting of experimental results and reviewing literature to formulate new approaches.

Nice-to-Have

* Master's degree and 4+ years of relevant experience.
* Experience with in vitro cardiomyocyte function assessments.
* Experience in rodent cardiac physiology assessments.
* Experience working in or collaborating with industry.

PHYSICAL/MENTAL REQUIREMENTS

* Will require standard laboratory physical work.

Other Job Details:

* Last Date to Apply for Job: March 29, 2021
* Eligible for Relocation Package: YES
* Eligible for Employee Referral Bonus: YES

LI-PFE

Sunshine Act

Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care providers name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.

EEO & Employment Eligibility

Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.

Research and Development

LI-PFE

Pfizer

New York, New York

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names.

Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Oncolytics Biotech Inc.; licensing agreement with BionTech AG; strategic alliance with Verily Life Sciences LLC; and collaboration agreements with Pfizer, Merck & Co., Inc., and Eli Lilly & Company, as well as with Merck KGaA and Nektar Therapeutics to develop a therapy for treating pancreatic cancer. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.